Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-22T17:50:36.057Z Has data issue: false hasContentIssue false
  • English
  • Français

Cost-Effectiveness of Pharmacological Treatment in Vascular Dementia

Published online by Cambridge University Press:  02 December 2014

Fadi Massoud
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Other
Information
Canadian Journal of Neurological Sciences , Volume 36 , Issue 6 , November 2009 , pp. 673 - 674
Copyright
Copyright © The Canadian Journal of Neurological 2009

References

1.Canadian Study of Health and Aging. Study methods and prevalence of dementia. CMAJ. 1994;150:899–913.Google Scholar
2.Burns, A, Lliffe, S.Dementia. BMJ. 2009;338:405–9.CrossRefGoogle ScholarPubMed
3.Feldman, H, Levy, AR, Hsiung, GY, Peters, KR, Donald, A, Black, SE, et al.A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results. Neuroepidemiology. 2003;22:265–74.Google Scholar
4.Chertkow, H.Diagnosis and treatment of dementia: introduction. CMAJ. 2009;178:316–21.CrossRefGoogle Scholar
5.Lopez, OL, Kuller, LH, Becker, JT, Jagust, WJ, DeKosky, ST, Fitzpatrick, A, et al.Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology. 2005;64:1539–47.CrossRefGoogle ScholarPubMed
6.Bruandet, A, Richard, F, Bombois, S, Maurage, CA, Deramecourt, V, Lebert, F, et al.Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:133–9.Google Scholar
7.Hachinski, V.Vascular dementia: a radical redefinition. Dementia. 1994;5:130–2.Google Scholar
8.Bowler, JV, Hachinski, V.Vascular cognitive impairment: a new approach to vascular dementia. Baillieres Clin Neurol. 1995;4:357–76.Google Scholar
9.O’Brien, JT, Erkinjuntti, T, Reisberg, B, Roman, G, Sawada, T, Pantoni, L, et al.Vascular cognitive impairment. Lancet Neurol. 2003;2:89–98.CrossRefGoogle ScholarPubMed
10.Hachinski, V, Iadecola, C, Petersen, RC, Breteler, MM, Nyenhuis, DL, Black, SE, et al.National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37:2220–41.Google Scholar
11.Grantham, C, Geerts, H.The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. J Neurol Sci. 2002;203-204:131–6.CrossRefGoogle Scholar
12.Roman, G, Kalaria, R.Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiol Aging. 2006;27:1769–85.CrossRefGoogle ScholarPubMed
13.Kavirajan, H, Schneider, LS.Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet Neurol. 2007;6:782–92.Google Scholar
14.Bocti, C, Black, S, Frank, C.Management of dementia with a cerebrovascular component. Alzheimers Dement. 2007;3:398–403.Google Scholar
15.Wong, CL, Bansback, N, Lee, PE, Anis, AH.Cost-effectiveness: cholinesterase inhibitors and memantine in vascular dementia. Can J Neurol Sci. 2009;36:735–9.CrossRefGoogle ScholarPubMed